Hoth Therapeutics Reports Positive Resuts for Potential Cancer Treatment Side Effect Drug - Shares up Pre-Bell

MT Newswires Live09-05

Hoth Therapeutics (HOTH) said Thursday it received positive data for the treatment of epidermal growth factor receptor inhibitor-associated papulopustular eruptions with its therapy HT-001.

In the first human case, the patient was able to stop treatment after one week, the company said, adding that the results mark "a significant advancement" in managing side effects in cancer patients undergoing epidermal growth factor receptor inhibitor therapy.

A phase 2a clinical trial is currently underway to further evaluate HT-001.

Shares of the company were up more than 43% in Thursday's premarket activity.

Price: 1.0000, Change: +0.31, Percent Change: +43.97

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2465546110?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-05 20:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2465546110","market":"sh","top_or_hot":-1,"title":"Hoth Therapeutics Reports Positive Resuts for Potential Cancer Treatment Side Effect Drug - Shares up Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/HOTH\">Hoth Therapeutics</a> (HOTH) said Thursday it received positive data for the treatment of epidermal growth factor receptor inhibitor-associated papulopustular eruptions with its therapy HT-001.</p><p>In the first human case, the patient was able to stop treatment after one week, the company said, adding that the results mark \"a significant advancement\" in managing side effects in cancer patients undergoing epidermal growth factor receptor inhibitor therapy.</p><p>A phase 2a clinical trial is currently underway to further evaluate HT-001.</p><p>Shares of the company were up more than 43% in Thursday's premarket activity.</p><p>Price: 1.0000, Change: +0.31, Percent Change: +43.97</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hoth Therapeutics Reports Positive Resuts for Potential Cancer Treatment Side Effect Drug - Shares up Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHoth Therapeutics Reports Positive Resuts for Potential Cancer Treatment Side Effect Drug - Shares up Pre-Bell\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-05 20:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hoth Therapeutics (HOTH) said Thursday it received positive data for the treatment of epidermal growth factor receptor inhibitor-associated papulopustular eruptions with its therapy HT-001.In the ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2465546110","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2465546110","pubTimestamp":1725540821,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hoth Therapeutics  said Thursday it received positive data for the treatment of epidermal growth factor receptor inhibitor-associated papulopustular eruptions with its therapy HT-001.In the first human case, the patient was able to stop treatment after one week, the company said, adding that the results mark \"a significant advancement\" in managing side effects in cancer patients undergoing epidermal growth factor receptor inhibitor therapy.A phase 2a clinical trial is currently underway to further evaluate HT-001.Shares of the company were up more than 43% in Thursday's premarket activity.Price: 1.0000, Change: +0.31, Percent Change: +43.97","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","01611":"新火科技控股","HOTH":"Hoth Therapeutics","BK1167":"电子制造服务"},"translate_title":"Hoth Therapeutics报告潜在癌症治疗副作用药物的积极结果——盘前份额上升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HOTH":1,"01611":0.87},"content_text":"Hoth Therapeutics (HOTH) said Thursday it received positive data for the treatment of epidermal growth factor receptor inhibitor-associated papulopustular eruptions with its therapy HT-001.In the first human case, the patient was able to stop treatment after one week, the company said, adding that the results mark \"a significant advancement\" in managing side effects in cancer patients undergoing epidermal growth factor receptor inhibitor therapy.A phase 2a clinical trial is currently underway to further evaluate HT-001.Shares of the company were up more than 43% in Thursday's premarket activity.Price: 1.0000, Change: +0.31, Percent Change: +43.97","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2465546110"}